BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

KPTIQ upcoming catalysts

Karyopharm Therapeutics Inc: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 1 FDA event(s). Subscribe to KPTIQ (.ics).

Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Ruxolitinib, Bendamustine, Ibrutinib, Lenalidomide, Venetoclax, Oxaliplatin

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Karyopharm Therapeutics Inc KPTIQNCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphomaactive not recruiting244
2026-12 est.P2/P3Karyopharm Therapeutics Inc KPTIQNCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruiting501

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-23FDA approvalapprovedKARYOPHARM THERAPS KPTIQXPOVIOApproved 2026-04-23: XPOVIO (NDA212306 SUPPL18)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09 est.P2Karyopharm Therapeutics Inc KPTIQNCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisactive not recruiting112
2026-05-22P3Karyopharm Therapeutics Inc KPTIQNCT05611931 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaEndometrial Canceractive not recruiting257
2026-02-20P3Karyopharm Therapeutics Inc KPTIQNCT04562389 Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisMyelofibrosisactive not recruiting353
2025-12 est.P1/P2Karyopharm Therapeutics Inc KPTIQNCT04607772 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLRelapsed or Refractory Diffuse Large B-Cell Lymphomawithdrawn

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.